Publication and Scientific Presentations

2019

Iovance Gen 2 TIL Manufacturing Process Produces Drug Products that Exhibit Favorable Quality Attributes for Adoptive Cell Transfer Across 5 Solid Tumor Indications PDF Poster | SITC Annual Meeting, November 6-10, 2019 | National Harbor, MD

Seth Wardell¹, Maritza Lienlaf-Moreno¹, Michelle Blaskovich¹, Ian Frank¹, Virginia Van Grod¹, Maria Fardis¹ and Joseph Wypych¹

¹Iovance Biotherapeutics, Inc. Tampa, FL and San Carlos, CA, USA

Safety and efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update PDF Poster | SITC Annual Meeting, November 6-10, 2019 | National Harbor, MD

Amod Sarnaik, MD¹, Nikhil I. Khushalani, MD¹,Jason Alan Chesney, MD, PhD², Harriet M. Kluger, MD³, Brendan D. Curti, MD⁴, Karl D. Lewis, MD⁵, Theresa Medina, MD⁵, Sajeve Samuel Thomas, MD⁶,  Anna C. Pavlick, MD, MBA⁷, Eric D. Whitman, MD⁸, Salvador Algarra⁹, Pippa Corrie, PhD, BMBCh, FRCP ¹⁰, Omid Hamid, MD¹¹, Jose Lutzky, MD¹², Judit Oláh, MD, DSc¹³, Jeffrey S. Weber, MD, PhD⁷, James M. G. Larkin, MD, PhD¹⁴, Wen Shi, MD, PhD¹⁵, Kelly DiTrapani, RN, BSN, BA¹⁵, Harry Qin, PhD¹⁵, Mariam Mirgoli¹⁵, Renee Wu, PhD¹⁵, Toshimi Takamura, BS¹⁵, Maria Fardis, PhD, MBA¹⁵, John M. Kirkwood, MD¹⁶

¹H. Lee Moffitt Cancer Center, Tampa, FL, USA; ²James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA; ³Yale University School of Medicine, Smilow Cancer Center, New Haven Hospital, New Haven, CT, USA; ⁴Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR, USA; ⁵University of Colorado Cancer Center – Anschutz Medical Campus , Aurora, CO, USA; ⁶University of Florida Health Cancer Center at Orlando Health, Orlando, FL, USA; ⁷Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY, USA; ⁸Atlantic Health System Cancer Care, Morristown, NJ, USA; ⁹Clínica Universidad de Navarra, Pamplona, Spain; ¹⁰Cambridge University Hospitals NHS Foundation Trust – Addenbrooke’s Hospital, Cambridge, UK; ¹¹The Angeles Clinic and Research Institute, Los Angeles, CA, USA; ¹²Mount Sinai Comprehensive Cancer Center, Miami, FL, USA; ¹³University of Szeged – Albert Szent-Györgyi Health Center, Szegedi, Hungary; ¹⁴Royal Marsden NHS Foundation Trust, London, UK; ¹⁵Iovance Biotherapeutics, Inc. San Carlos, CA, USA; ¹⁶Hillman Cancer Center – University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Expanding Iovance’s tumor infiltrating lymphocytes (TIL) from core biopsies for adoptive T cell therapy using a 22-day manufacturing process PDF Poster | SITC Annual Meeting, November 6-10, 2019 | National Harbor, MD

Michelle R. Simpson-Abelson¹, Angel Hilton¹, Kenneth D’Arigo¹, Maria Fardis¹, and Cécile Chartier¹

¹Iovance Biotherapeutics, Inc. Tampa, FL and San Carlos, CA, USA

Silencing PD-1 using self-delivering RNAi PH-762- to improve Iovance TIL effector function using Gen 2 manufacturing method PDF Poster | SITC Annual Meeting, November 6-10, 2019 | National Harbor, MD

Inbar Azoulay Alfaguter¹, Michelle Simpson-Abelson¹, Krit Ritthipichai¹, Kenneth D’Arigo¹, Florangel Hilton¹, Marcus Machin¹, Dingxue Yan², James Cardia², Maria Fardis¹, and Cécile Chartier

¹Iovance Biotherapeutics, Inc. Tampa, FL and San Carlos, CA, USA; ²Phio Pharmaceuticals Marlborough, MA, USA

Iovance Peripheral Blood Lymphocytes (PBL): A Potential Cell Therapy Strategy For The Treatment of Chronic Lymphocytic Leukemia PDF Poster | European Hematologic Association Annual Congress – June 13-16, 2019 | Amsterdam

Lavakumar Karyampudi¹, Michelle Blaskovich^*1, Ian Frank^*1, Nermin Gerges¹, Amanda Stramer¹, Arvind Natarajan¹, Meixiao Long², Cecile Chartier¹, John Byrd², Maria Fardis¹

¹Iovance Biotherapeutics, Inc., San Carlos, CA, USA; ²The Ohio State University, Columbus, OH, USA. *Authors contributed equally to this work.

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1 PDF Poster | ASCO Annual Meeting, May 31 – June 4, 2019 | Chicago

Amod Sarnaik¹, Nikhil I. Khushalani¹, Jason Alan Chesney², Harriet M. Kluger³, Brendan D. Curti⁴, Karl D. Lewis⁵, Sajeve Samuel Thomas⁶, Eric D. Whitman⁷, Omid Hamid⁸, Jose Lutzky⁹, Anna C. Pavlick¹⁰, Jeffrey S. Weber¹⁰, James M.G. Larkin¹¹, Debora Barton¹², Kelly DiTrapani¹², Renee Wu¹², Maria Fardis¹², John M. Kirkwood¹³

¹H. Lee Moffitt Cancer Center, Tampa, FL; ²James Graham Brown Cancer Center, University of Louisville, Louisville, KY;  ³Yale School of Medicine, New Haven, CT; ⁴Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR; ⁵University of Colorado Comprehensive Cancer Center, Aurora, CO; ⁶University of Florida Health Cancer Center at Orlando Health, Orlando, FL; ⁷Atlantic Health System Cancer Care, Morristown, NJ;  ⁸The Angeles Clinic and Research Institute, Los Angeles, CA; ⁹Mount Sinai Comprehensive Cancer Center, Miami, FL; ¹⁰Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY; ¹¹Royal Marsden NHS Foundation Trust, London, United Kingdom; ¹²Iovance Biotherapeutics, Inc., San Carlos, CA; ¹³Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA

Safety & efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma PDF Poster | ASCO Annual Meeting, May 31 – June 4, 2019 | Chicago

Amir A. Jazaeri¹, Emese Zsiros², Rodabe Navroze Amaria¹, Andrew S. Artz³, Robert P. Edwards⁴, Robert Michael Wenham⁵, Brian M. Slomovitz⁶, Axel Walther⁷, Sajeve Samuel Thomas⁸, Jason Alan Chesney⁹, Robert Morris¹⁰, Koji Matsuo¹¹, Stephanie Gaillard¹², Peter G. Rose¹³, Jesus Garcia Donas¹⁴, Jacqueline Maria Tromp¹⁵, Kelly DiTrapani¹⁶, Huiling Li¹⁶, Maria Fardis¹⁶, Bradley J. Monk¹⁷

¹The University of Texas – MD Anderson Cancer Center, Houston, TX; ²Roswel Park Cancer Institute, Buffalo, NY; ³University of Chicago Comprehensive Cancer Center, Chicago, IL; ⁴Hillman Cancer Institute University of Pittsburgh Medical Center, Pittsburgh, PA; ⁵H. Lee Moffitt Cancer Center, Tampa, FL; ⁶Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL; ⁷University Hospitals Bristol, Bristol, United Kingdom; ⁸University of Florida Health Cancer Center at Orlando Health, Orlando, FL; ⁹James Graham Brown Cancer Center, University of Louisville, Louisville, KY; ¹⁰Barbara A. Karmanos Cancer Center, Wayne State University, Detroit, MI; ¹¹Los Angeles County Hospital-University of Southern California, Los Angeles, CA; ¹²Johns Hopkins School of Medicine, Baltimore, MD; ¹³Cleveland Clinic Foundation, Cleveland, OH; ¹⁴Hospital Universitario Madrid Sanchinarro, Madrid, Spain; ¹⁵Academical Medical Center, Amsterdam, Netherlands; ¹⁶Iovance Biotherapeutics, Inc., San Carlos, CA; ¹⁷University of Arizona Cancer Center at Dignity Health St. Joseph’s Hospital and Medical Center, Phoenix, AZ

A Phase 2 study of autologous tumor infiltrating lymphocytes (TIL; lifileucel [LN-144]/LN-145) in patients with solid tumors PDF Poster | ASCO Annual Meeting, May 31 – June 4, 2019 | Chicago

Jason Chesney¹, Jose Lutzky², Sajeve Samuel Thomas³, Jorge Nieva⁴, Eva Muñoz Couselo⁵, Juan Francisco Moreno Rodriguez⁶, Juan Jesus Martin-Liberal⁷, Alex Cacovean⁸, Huiling Li⁸, Zelanna Goldberg⁸, Maria Fardis⁸, Scott Gettinger⁹

¹James Graham Brown Cancer Center, Louisville, KY; ²Mount Sinai Comprehensive Cancer Center, Miami Beach, FL; ³University of Florida Health Cancer Center, Orlando, FL; ⁴USC Norris Cancer Center, Los Angeles, CA; ⁵Hospital Universitario Vall d’Hebron – PPDS, Barcelona, ES; ⁶Hospital Universitario HM Sanchinarro – CIOCC, Madrid, ES; ⁷ICO l’Hospitalet – Hospital Duran i Reynals, Barcelona, ES; ¹³Iovance Biotherapeutics, San Carlos, CA; ⁹Yale Cancer Center, New Haven, CT

Expansion of tumor-infiltrating lymphocytes (TIL) using Iovance’s Gen 2 process from bladder cancer for adoptive immunotherapy PDF Poster | AACR Meeting – Bladder Cancer: Transforming the Field, May 18-21, 2019 | Denver

Qiang John Li, Khurshid Guru, Amit Lugade, Elizabeth Brese, Kunle Odunsi, Anand Veerapathran, Kenneth Onimus, Adrian Wells, Cécile Chartier, Arvind Natarajan, Maria Fardis, Gurkamal Chatta

Persistence of cryopreserved tumor-infiltrating lymphocyte product lifileucel (LN-144) in C-144-01 study of advanced metastatic melanoma PDF Poster | AACR Annual Meeting,  March 29-April 03, 2019 | Atlanta

Viktoria Gontcharova, Sam Suzuki, Michelle Abelson, Michelle Blaskovich, Cécile Chartier

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progression on checkpoint inhibitors PDF Poster | ASCO-SITC Clinical Immuno-Oncology Symposium,  February 28-March 02, 2019 | San Francisco

Amod Sarnaik¹, Sajeve Samuel Thomas², Diwakar Davar³, John M. Kirkwood³, Harriet Kluger⁴, Jose Lutzky⁵, Melissa Wilson⁶, Anna C. Pavlick⁷, Brendan Curti⁸, Eric Whitman⁹, Karl Lewis¹⁰, Giao Phan¹¹, Omid Hamid¹², Evidio Domingo-Musibay¹³, Marc Ernstoff¹⁴, Hendrik-Tobias Arkenau¹⁵, Judit Olah¹⁶, Pippa Corrie¹⁷, Stéphane Dalle¹⁸, Salvador Algarra¹⁹, Gregory Daniels²⁰, Lavakumar Karyampudi²¹, Toshimi Takamura²¹, Debora Barton²¹, Sam Suzuki²¹, Nancy L. Samberg²¹, Maria Fardis²¹, Jason Chesney²²

2018

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progression on checkpoint inhibitors PDF Poster | SITC Annual Meeting,  November 9-11, 2018 | Washington, DC

Amod Sarnaik¹, Sajeve Samuel Thomas², Diwakar Davar³, John M. Kirkwood³, Harriet Kluger⁴, Jose Lutzky⁵, Melissa Wilson⁶, Anna C. Pavlick⁷, Brendan Curti⁸, Eric Whitman⁹, Karl Lewis¹⁰, Giao Phan¹¹, Omid Hamid¹², Evidio Domingo-Musibay¹³, Marc Ernstoff¹⁴, Hendrik-Tobias Arkenau¹⁵, Judit Olah¹⁶, Pippa Corrie¹⁷, Stéphane Dalle¹⁸, Salvador Algarra¹⁹, Gregory Daniels²⁰, Lavakumar Karyampudi²¹, Toshimi Takamura²¹, Debora Barton²¹, Sam Suzuki²¹, Nancy L. Samberg²¹, Maria Fardis²¹, Jason Chesney²²

 ¹Moffitt Cancer Center, Tampa, FL, USA; ²Univ. of Florida Health Cancer Center, Orlando, FL, USA; ³Univ. of Pittsburgh-Hillman Cancer Center, Pittsburgh, PA, USA ⁴Yale Cancer Center, New Haven, CT, USA; ⁵Mount Sinai Comprehensive Cancer Center, Miami Beach, FL, USA; ⁶Thomas Jefferson Kimmel Cancer Center, Philadelphia, PA, USA; ⁷NYU Perlmutter Cancer Center-Langone, New York, NY, USA; ⁸Earle A. Chiles Research Institute-Providence Cancer Center, Portland, OR, USA; ⁹Atlantic Health System Cancer Care, Morristown, NJ, USA; ¹⁰Univ. of Colorado Health Cancer Care-Anschutz Medical Campus; Aurora, CO, USA; ¹¹Virginia Commonwealth University-School of Medicine, Richmond, VA, USA; ¹² The Angeles Clinic, Los Angeles, CA, USA; ¹³Univ. of Minnesota Health-Masonic Cancer Center, Minneapolis, MN, USA ¹⁴ Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; ¹⁵Sarah Cannon Research Institute, London, UK ¹⁶Szegedi Tudomanyegyetem Szent-Györgyi Albert Klinikai Központ, Csongrad, HU; ¹⁷Addenbrooke’s Hospital, Cambridge, UK; ¹⁸Centre Hospitalier Lyon Sud, Rhone-Alpes, FR; ¹⁹Clínica Universidad de Navarra, Pamplona, Navarra, ES; ²⁰University of California San Diego-Moores Cancer Center, San Diego, CA, USA; ²¹Iovance Biotherapeutics, San Carlos, CA, USA; ²²James Graham Brown Cancer Center

PD1-positive tumor-infiltrating lymphocytes (TIL) for the next generation of adoptive T cell therapy PDF Poster | SITC Annual Meeting,  November 9-11, 2018 | Washington, DC

Michelle R. Simpson-Abelson, Kenneth D’Arigo, Angel Cedano-Hilton, Ian Frank, Viktoria Gontcharova, Krit Ritthipichai, and Cécile Chartier

A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma
PDF Poster | ASCO ANNUAL MEETING, JUNE 1-5, 2018 | CHICAGO
Abstract TPS9595 and poster number 422a – poster presented Monday, June 4^th
Amod Sarnaik¹, Brendan Curti², Diwakar Davar³, John M. Kirkwood³, Omid Hamid⁴, Jose Lutzky⁵, Melissa Wilson⁶, Harriet Kluger⁷, Eric Whitman⁸ , Giao Phan⁹, Sajeve Samuel Thomas¹⁰,Karl Lewis¹¹, Hendrik-Tobias Arkenau¹², Bente Larsen¹³, Igor Gorbatchevsky¹³, Corina Andresen¹³,  Sam Suzuki¹³, Nancy Samberg¹³, Maria Fardis¹³, Jason Chesney^{14 1}Moffitt Cancer Center, Tampa, FL; ²Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR; ³University of Pittsburgh Medical Center – Hillman Cancer Center, Pittsburgh, PA; ⁴The Angeles Clinic and Research Institute, Los Angeles, CA; ⁵Mount Sinai Comprehensive Cancer Center, Miami Beach, FL; ⁶New York University – Perlmutter Cancer Center – Langone Medical Center, New York, NY; ⁷Yale Cancer Center, New Haven, CT; ⁸ Atlantic Health System Cancer Care, Morristown, NJ; ⁹Virginia Commonwealth University, Richmond, VA; ¹⁰University of Florida Health Cancer Center, Orlando, FL; ¹¹University of Colorado Cancer Center, Denver CO; ¹²Sarah Cannon Research Institute London UK; ¹³Iovance Biotherapeutics, San Carlos, CA; ¹⁴James Graham Brown Cancer Center, Louisville, KY

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
PDF Poster | ASCO ANNUAL MEETING, JUNE 1-5, 2018 | CHICAGO
Abstract TPS6096 and poster number 81a – poster presented Saturday, June 2^nd 
Rom Leidner¹, Ammar Sukari², Christine Chung³, James Ohr⁴, Missak Haigentz⁵, Ezra E. W. Cohen⁶, Robert J. Brown⁷, Igor Gorbatchevsky⁷, Sam Suzuki⁷, Maria Fardis⁷, Robert L. Ferris^{4 1}Earle A. Chiles Research Institute – Providence Cancer Center, Portland, OR;  ²Barbara Ann Karmanos Cancer Institute, Detroit, MI;  ³Moffitt Cancer Center, Tampa, FL;  ⁴University of Pittsburgh Medical Center, Pittsburgh, PA; ⁵Morristown Medical Center/Atlantic Health System, Morristown, NJ; ⁶University of California, San Diego, CA; ⁷Iovance Biotherapeutics, San Carlos, CA

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma 
PDF Poster | ASCO ANNUAL MEETING, JUNE 1-5, 2018 | CHICAGO
Amir Jazaeri¹, Robert Edwards², Robert Wenham³, Koji Matsuo⁴, Gini F. Fleming⁵, David M. O’Malley⁶, Brian Slomovitz⁷, Bradley Monk⁸, Robert J. Brown⁹, Igor Gorbatchevsky⁹, Sam Suzuki⁹, Maria Fardis⁹, Emese Zsiros^{10  1}MD Anderson Cancer Center, Houston, TX; ²University of Pittsburgh Medical Center – Hillman Cancer Center, Pittsburgh, PA; ³Moffitt Cancer Center, Tampa, FL; ⁴Norris Cancer Center, University of Southern California, Los Angeles, CA; ⁵University of Chicago, Chicago, IL; ⁶The James Cancer Center, Ohio State University, Columbus, OH; ⁷Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; ⁸Arizona Oncology, University of Arizona College of Medicine, and Phoenix Creighton University School of medicine at St. Joseph’s Hospital, Phoenix, AZ;  ⁹Iovance Biotherapeutics, San Carlos, CA; ¹⁰Roswell Park Cancer Institute, Pittsburgh, PA

Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combination with Anti-PD-L1 Inhibitor Durvalumab (MEDI4736) in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
PDF Poster | ASCO ANNUAL MEETING, JUNE 1-5, 2018 | CHICAGO
Sylvia Lee¹, Liza Villaruz², Susie Tanamly³, Igor Gorbatchevsky³, Corina Andresen³,  Sam Suzuki³, Maria Fardis³, Missak Haigentz^{4   1}University of Washington, Seattle, WA; ²University of Pittsburgh Medical Center – Hillman Cancer Center, Pittsburgh, PA; ³Iovance Biotherapeutics, San Carlos, CA; ⁴Atlantic Health System/Morristown Medical Center, Morristown, NJ

A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma
PDF Poster | AACR ANNUAL MEETING, APRIL 14-18, 2018 | CHICAGO
Amod Sarnaik¹, Brendan Curti², Diwakar Davar³, Omid Hamid⁴, Jose Lutzky⁵, Melissa Wilson⁶, Harriet Kluger⁷, Jason Chesney⁸, Kevin Kim⁹, Giao Phan¹⁰, Sajeve Thomas¹¹, Igor Gorbatchevsky¹², Bente Larsen¹², Sam Suzuki¹², Nancy Samberg¹², Maria Fardis¹², John M. Kirkwood³

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
PDF Poster | AACR ANNUAL MEETING, APRIL 14-18, 2018 | CHICAGO
Rom Leidner¹, Ammar Sukari², Christine Chung³, James Ohr⁴, Missak Haigentz⁵, Ezra E. W. Cohen⁶, Robert J. Brown⁷, Igor Gorbatchevsky⁷, Sam Suzuki⁷, Maria Fardis⁷, Robert L. Ferris⁴

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma
PDF Poster | AACR ANNUAL MEETING, APRIL 14-18, 2018 | CHICAGO
Amir Jazaeri¹, Robert Edwards², Robert Wenham³, Koji Matsuo⁴, Gini F. Fleming⁵, David M. O’Malley⁶, Brian Slomovitz⁷, Bradley Monk⁸, Robert J. Brown⁹, Igor Gorbatchevsky⁹, Sam Suzuki⁹, Maria Fardis⁹, Emese Zsiros¹⁰

Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combination with Anti-PD-L1 Inhibitor Durvalumab (MEDI4736) in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
PDF Poster | AACR ANNUAL MEETING, APRIL 14-18, 2018 | CHICAGO
Sylvia Lee¹, Liza Villaruz², Susie Tanamly³, Igor Gorbatchevsky³, Sam Suzuki³, Maria Fardis³, Missak Haigentz⁴

Anti-OX40 Agonistic Antibody Enhances ex vivo CD8+ TIL Expansion with Increased T-cell Effector Function
PDF Poster | AACR ANNUAL MEETING, APRIL 14-18, 2018 | CHICAGO
Krit Ritthipichai, Marcus Machin, Maria Fardis, and Cecile Chartier

2017

Novel Cryopreserved Tumor Infiltrating Lymphocytes (LN-144) Administered to Patients with Metastatic Melanoma Demonstrates Efficacy and Tolerability in a Multicenter Phase 2 Clinical Trial
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD
Amod Sarnaik¹, Jason Chesney², Harriet Kluger³, Brendan Curti⁴, Omid Hamid⁵, Jose Lutzky⁶, Maria Fardis⁷, Igor Gorbatchevsky⁷, Sam Suzuki⁷, Bente Larsen⁷, Nancy L. Samberg⁷, John Kirkwood⁸

A Cryopreserved Tumor Infiltrating Lymphocyte (TIL) Product for LN-144, Generated with an Abbreviated Method Suitable for High Throughput Commercial Manufacturing Exhibits Favorable Quality Attributes For Adoptive Cell Transfer
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD
Seth Wardell, Ian Frank, Lavakumar Karyampudi, Anand Veerapathran, Michelle Simpson-Abelson, Maritza Lienlaf Moreno, Michelle Blaskovich, Joseph Wypych, and Maria Fardis

Studies of Key Quality Attributes for TIL Product, LN-144
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD
Krit Ritthipichai, Ian Frank, Marcus Machin, Michelle Blaskovich, Amanda Stramer, Michelle Simpson-Abelson, Maria Fardis, Cecile Chartier

A phase 2 study to evaluate the safety and efficacy of using of using autologous tumor infiltrating lymphocytes (LN -145) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD
Leidner R¹, Ohr J², Chung C³, Brown RJ⁴, Suzuki S⁴, Gorbatchevsky I⁴, Fardis M⁴, and Ferris RL²

A phase 2, multicenter study to evaluate the efficacy and safety of using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD
Amir Jazaeri¹, Robert Edwards², Emese Zsiros³, Robert Brown⁴, Igor Gorbatchevsky⁴, Sam Suzuki⁴, Maria Fardis⁴, Robert Wenham⁵

The T-cell Growth Factor Cocktail IL-2/IL-15/IL-21 Enhances Expansion and Effector Function of Tumor-Infiltrating T cells in a Novel Process Developed by Iovance
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD
Michelle R. Simpson-Abelson, Christopher Mosychuk, Ian Frank, Krit Ritthipichai, and Cecile Chartier

Phenotypic and Functional Characterization of Tumor Infiltrating Lymphocytes (TIL) Grown from Non-Hodgkin Lymphoma Tumors – Implications for the Development of Novel Therapies for Lymphoma
PDF Poster | ESMO Annual Meeting, September 7-12, 2017 | Madrid
Lavakumar Karyampudi, Aishwarya Gokuladass, Michelle Blaskovich, Maria Fardis, Michael T Lotze

TIL Candidate Shows Potential in Metastatic Melanoma Based on Interim Data
News Feature | Drug Discovery & Development, 06/23/2017

Efficacy of Single Administration of Tumor Infiltrating Lymphocytes (TIL) in Heavily Pre-Treated Metastatic Melanoma Patients Following Checkpoint Therapy
PDF Poster | ASCO Annual Meeting 2017
Amod Sarnaik, Harriet Kluger, Jason Chesney, Jyothi Sethuraman, Michael T. Lotze, Bente Larsen, Igor Gorbatchevsky, Nancy L. Samberg, Sam Suzuki, Lei Wang, Mariam Mirgoli, Maria Fardis, Brendan Curti

K+ Channel Activation Promotes Tumor Infiltrating Lymphocyte (TIL) Expansion and Enhances Expression of CCR7
PDF Poster | AAI Annual Meeting 2017
Krit Ritthipichai, Marcus Machin, Michelle Simpson-Abelson, Christopher Mosychuk, Anand Veerapathran, and Michael T. Lotze

Emigrant Tumor Infiltrating Lymphocytes Profoundly Differ from Remnant T cells
PDF Poster | AACR Annual Meeting 2017
Michelle R. Simpson-Abelson, Christopher Mosychuk, Maria Fardis, and Michael T. Lotze

2016

P14 Bioluminescent redirected lysis assay (BRLA) as an efficient potency assay to assess tumor-infiltrating lymphocytes (TILs) for immunotherapy
PDF Poster | Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82, DOI 10.1186/s40425-016-0172-7
Aishwarya Gokuldass, Michelle A Blaskovich, Charlene Kopits, Brian Rabinovich, Michael T. Lotze

P11 Stable tumor-infiltrating lymphocytes (TIL) phenotype following cryopreservation
PDF Poster | Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82, DOI 10.1186/s40425-016-0172-7
Ian Frank, Amanda Stramer, Michelle A Blaskovich, Seth Wardell, Maria Fardis, James Bender, Michael T Lotze

P41 Successful expansion and characterization of tumor infiltrating lymphocytes (TILs) from non-melanoma tumors
PDF Poster | Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82, DOI 10.1186/s40425-016-0172-7
Jyothi Sethuraman, Laurelis Santiago, Jie Qing Chen, Zhimin Dai, Seth Wardell, James Bender, Michael T Lotze

P46 Artificial antigen presenting cells promote expansion of tumor infiltrating lymphocytes (TILs)
PDF Poster | Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82, DOI 10.1186/s40425-016-0172-7
Anandaraman Veerapathran, Aishwarya Gokuldass, Amanda Stramer, Jyothi Sethuraman, Michelle A Blaskovich, Doris Wiener, Ian Frank, Laurelis Santiago, Brian Rabinovich, Maria Fardis, James Bender, Michael T Lotze

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma
PubMed | Journal of Clinical Oncology 2016 34:20, 2389-2397, doi: 10.1200/JCO.2016.66.7220
Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, Lu L, Kwong MLM, Ilyas S, Klemen ND, Payabyab EC, Morton KE, Toomey MA, Steinberg SM, White DE, and Rosenberg SA

2015

Adoptive cell transfer as personalized immunotherapy for human cancer
Science | Science 03 Apr 2015, Vol. 348, Issue 6230, pp. 62-68, DOI 10.1126/science.aaa4967
Rosenberg SA, and Restifo NP

Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.
PubMed | Clin Cancer Res. 2015;21(3):611-21
Chacon JA, Sarnaik AA, Chen JQ, et al.

2014

Finding suitable targets is the major obstacle to cancer gene therapy
Nature | Cancer Gene Ther. 2014;21(2):45-7
Rosenberg SA

Exploiting the curative potential of adoptive T-cell therapy for cancer
PubMed | Immunol Rev. 2014;257(1):56-71
Hinrichs CS, Rosenberg SA